Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

European Journal of Heart Failure(2022)10.1002/ejhf.2722Source: DataRank Database

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan is a research paper published in European Journal of Heart Failure (2022). On theSindex it has a DataRank of 0. It has been cited 34 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access34 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.63)OA: hybridTopics (68)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (21)

Jawad H. Butt ORCID,Toru Kondo ORCID,Karola Jering ORCID,Kieran F. Docherty ORCID,Pardeep S. Jhund ORCID

Live enrichment

PubMed:36342375 PMC:PMC11497302 OpenAlex:https://openalex.org/W4308372799

British Heart Foundation

Grant: RE/18/6/34217

National Institutes of Health

Grant: 2T32HL007604-06

TRAINING PROGRAM IN CARDIOVASCULAR RESEARCH

British Heart Foundation

China Scholarship Council

FWCI

3.63

Citation Percentile

0.9%

Citation Trend

2013

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2722

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2722

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2722

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/ejhf.2722

journalhttps://doi.org/10.1002/ejhf.2722

Fields of Study

Diabetes Treatment and ManagementHormonal Regulation and HypertensionHeart Failure Treatment and Management03 medical and health sciences0302 clinical medicineMaleHumansHeart FailureMineralocorticoid Receptor AntagonistsStroke VolumeTetrazolesAngiotensin Receptor AntagonistsValsartanAminobutyratesBiphenyl CompoundsDrug CombinationsHypotensionBenzhydryl CompoundsGlucosides

MeSH Terms

ValsartanMineralocorticoid Receptor AntagonistsAminobutyratesBenzhydryl CompoundsBiphenyl CompoundsDrug CombinationsGlucosidesHeart FailureHumansHypotensionMaleStroke VolumeTetrazolesAngiotensin Receptor Antagonists

Keywords

DapagliflozinMedicineEjection fractionHeart failureInternal medicinePlaceboHazard ratioSacubitrilCardiologyValsartanHeart failure with preserved ejection fractionBlood pressureConfidence intervalSacubitril, ValsartanEndocrinologyDiabetes mellitusType 2 diabetesAldosteroneNeprilysinMineralocorticoid Receptor AntagonistSodium-glucose Cotransporter 2Sacubitril/valsartanMaleAminobutyratesBiphenyl CompoundsSglt2 InhibitorsTetrazolesStroke VolumeAngiotensin Receptor AntagonistsDrug CombinationsGlucosidesHumansHypotensionBenzhydryl CompoundsMineralocorticoid Receptor Antagonists

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being